CPT1A and Stroke: While preclinical models highlight promising targets such as CPT1A inhibitors to quell neuroinflammation and ACMSD modulators to boost NAD+, these interventions often falter in clinical trials, not merely due to interspecies metabolic differences but because human stroke recovery is entangled with aging, lifestyle, and systemic inequities [237, 238].